Bio News
The US Food and Drug Administration (FDA) approved Jazz Pharmaceuticals’ cancer drug Ziihera as a first-line treatment for HER2-positive gastroesophageal adenocarcinoma. In a phase 3 trial comparing Ziihera with Roche’s Herceptin, Ziihera reduced the risk of disease progression or death by 35% and the risk of death by 28%. With the approval, Jazz secured a market opportunity worth more than $1.5 billion targeting approximately 12,000 patients in the US alone.
BIOBOOK TEAM
biobookmedia@biobook.co.krRural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
HLB Submits FDA Resubmission for First-Line Liver Cancer Treatment
Celltrion Reports Third-Quarter Revenue of 1.5 Trillion Won and Operating Profit of 510 Billion Won, Up 69% Year Over Year
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
